含CpG 1018佐剂的在研究性Tdap加强疫苗与Boostrix在健康成人和青少年中比较的1期试验
这项随机、活性对照、多中心、剂量递增1期试验在10至22岁健康参与者中比较Tdap-1018 1500 μg、Tdap-1018 3000 μg与Boostrix的安全性及免疫原性。两种Tdap-1018配方总体耐受良好,无疫苗相关严重不良事件;在成人中3000 μg组对百日咳毒素和破伤风抗体的几何平均浓度比及加强应答率显著高于Boostrix,青少年中3000 μg组所有抗原的几何平均浓度比和加强应答率与Boostrix相似或更高。
要点
- 两种Tdap-1018配方总体耐受良好,无疫苗相关严重不良事件。
- 成人3000 μg组抗百日咳毒素和抗破伤风GMC比显著高于Boostrix。
- 成人3000 μg组抗百日咳毒素、抗百日咳杆菌黏附素和抗破伤风BRR显著高于Boostrix。
核心结论
- Tdap-1018 3000 μg诱导的免疫应答与Boostrix相似或更高,两种Tdap-1018配方安全性及耐受性可接受。
研究设计与样本
- 随机、活性对照、多中心、剂量递增1期试验,健康参与者年龄10至22岁,接受1剂Tdap-1018 1500 μg、Tdap-1018 3000 μg或Boostrix。
- 共入组117名参与者,80名成人(92%)和30名青少年(100%)完成研究。
- 接种后4周评估百日咳(百日咳毒素、丝状血凝素、百日咳杆菌黏附素)、破伤风和白喉抗原抗体及百日咳毒素中和抗体,接种后7天内评估征集性注射后反应,接种后12周内评估非征集性不良事件。
主要发现
- 两种Tdap-1018配方总体耐受良好,无疫苗相关严重不良事件。
- Tdap-1018注射后反应频率和严重程度与Boostrix相似,但Tdap-1018中度疼痛比例更高。
- 成人第4周3000 μg组所有抗原的GMC比和BRR与Boostrix相似或更高,抗百日咳毒素GMC比为2.1(1.5-3.0),抗破伤风GMC比为1.8(1.1-2.9)。
- 成人3000 μg组抗百日咳毒素BRR差异为34.5%(95%CI 13.4-54.6),抗百日咳杆菌黏附素BRR差异为19.2%(95%CI 4.4-38.1),抗破伤风BRR差异为30.0%(95%CI 3.6-52.7)。
- 青少年3000 μg组所有抗原的GMC比和BRR与Boostrix相似或更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This phase 1 trial assessed the safety and immunogenicity of an investigational tetanus/diphtheria/acellular pertussis vaccine combined with CpG 1018 adjuvant 1500 μg (Tdap-1018 1500 μg) or 3000 μg (Tdap-1018 3000 μg) in adults and adolescents. In this randomized, active-controlled, multicenter, dose-escalation trial, healthy participants aged 10 to 22 years received 1 dose of Tdap-1018 1500 μg, Tdap-1018 3000 μg, or Boostrix. Geometric mean concentrations (GMCs) and booster response rates (BRRs) for antibodies against pertussis (pertussis toxin, filamentous hemagglutinin, pertactin), tetanus, and diphtheria antigens, and neutralizing antibodies against pertussis toxin were assessed 4 weeks after vaccination. Safety and tolerability were assessed for solicited post-injection reactions within 7 days after vaccination and unsolicited adverse events up to 12 weeks after vaccination. Of 117 enrolled participants, 80 adults (92%) and 30 adolescents (100%) completed the study. Both Tdap-1018 formulations were generally well tolerated, with no vaccine-related serious adverse events. Frequency and severity in post-injection reactions after Tdap-1018 administration were similar to Boostrix except for higher proportions of moderate pain for Tdap-1018. In adults at week 4, ratio of GMCs and BRRs for all antigens in the 3000-μg group were similar to or higher than Boostrix, with significantly higher GMC ratios for anti-pertussis toxin (2.1 [1.5-3.0]) and anti-tetanus (1.8 [1.1-2.9]) and significantly higher BRRs for anti-pertussis toxin (difference [95% CI]: 34.5% [13.4-54.6]), anti-pertactin (19.2% [4.4-38.1]), and anti-tetanus (30.0% [3.6-52.7]) antibodies. For adolescents, in the 3000-μg group, ratio of GMCs and BRRs were similar to or higher than Boostrix for all antigens. Both Tdap-1018 formulations showed acceptable safety and tolerability profiles. Tdap-1018 3000 μg induced similar or higher immune responses than Boostrix. ACTRN12620001177943 (Australian New Zealand Clinical Trials Registry; https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12620001177943p).
引用
- Richmond P, Nolan T, McGirr A, et al. Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents. Vaccine. 2024. PMID: 39226786. doi:10.1016/j.vaccine.2024.126251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。